ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 82 citations in OpenAlex.
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.International psychogeriatrics · 2024Trial
- Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.The journal of prevention of Alzheimer's disease · 2024Trial
- Effects of Meditation Training and Non-Native Language Training on Cognition in Older Adults: A Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Disruption of temporo-parietal network in Alzheimer's disease and its association with memory impairment.Alzheimer's research & therapy · 2026Observational
- Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Combining p-tau217 and digital cognitive testing to predict cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Visual memory correlates with AD biomarkers in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cortical mean diffusivity detects early age-related changes and associates with cognition and plasma biomarkers.Brain communications · 2026Article
- Physical activity as a modifiable risk factor in preclinical Alzheimer's disease.Nature medicine · 2025Article
- Using memory recall response time on digital cognitive testing to detect subtle cognitive changes among cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Development and Preliminary Validation of Standardized Regression-Based Change Scores as Measures of Transitional Cognitive Decline.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2025Article
- Assessing Stages of Objective Memory Impairment and neuroimaging as risk factors of incident cognitive impairment.Journal of the International Neuropsychological Society : JINS · 2025Article
- PTSD moderates the association between subjective cognitive decline and Alzheimer's disease biomarkers in older veterans.Aging & mental health · 2025Article
- Detecting early cognitive deficits in preclinical Alzheimer's disease using a remote digital multi-day learning paradigm.NPJ digital medicine · 2025Article
- Self- and study partner-reported cognitive decline in older adults without dementia: The role of α-synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Amyloid-PET imaging predicts functional decline in clinically normal individuals.Alzheimer's research & therapy · 2024Article
- Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.Annals of neurology · 2024Article
- Increased intraindividual variability in reaction time performance is associated with emerging cognitive decline in cognitively unimpaired adults.Neuropsychology · 2024Article
- Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients.Current Alzheimer research · 2024Article
- Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.Neurology · 2023Observational
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
Abstract
introductionDemonstrating the "clinical meaningfulness" of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid-β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression.
methodsCox regression analyses were used to determine whether 3-year slopes on the preclinical Alzheimer's cognitive composite predicted MCI diagnosis and global Clinical Dementia Rating>0 in 267 Aβ+ CN individuals participating in the Harvard Aging Brain Study, Australian Imaging, Biomarker and Lifestyle Study, and Alzheimer's Disease Neuroimaging Initiative.
resultsSteeper preclinical Alzheimer's cognitive composite decline over 3 years was associated with increased risk for MCI diagnosis and global Clinical Dementia Rating>0 in the following years across all cohorts. Hazard ratios using meta-analytic estimates were 5.47 (95% CI: 3.25-9.18) for MCI diagnosis and 4.49 (95% CI: 2.84-7.09) for Clinical Dementia Rating>0 in those with subtle decline (>-.14 to -.26 preclinical Alzheimer's cognitive composite standard deviations/year) on longitudinal cognitive testing. DISCUSSION: Early "subtle cognitive decline" among Aβ+ CN on a sensitive cognitive composite demonstrably increases risk for imminent clinical disease progression and functional impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.